Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Neoadjuvant therapy in pancreatic cancer
Roderick M. Quiros
, Kimberly M. Brown
, John P. Hoffman
Research output
:
Contribution to journal
›
Review article
›
peer-review
46
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Neoadjuvant therapy in pancreatic cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Pancreatic Cancer
100%
Neoadjuvant Therapy
100%
Resectable Disease
50%
Chemoradiation
50%
United States
25%
Cancer Mortality
25%
Cancer Causes
25%
Adjuvant Therapy
25%
Surgical Resection
25%
Negative Resection Margin
25%
Postoperative Treatment
25%
Patient Selection
25%
Postoperative Recovery
25%
Surgery Alone
25%
Neoadjuvant
25%
Tumor Downstaging
25%
Postoperative Therapy
25%
Neoadjuvant Setting
25%
Medicine and Dentistry
Pancreas Cancer
100%
Neoadjuvant Therapy
100%
Chemoradiotherapy
50%
Postoperative Care
50%
Diseases
50%
Cancer Mortality
25%
Neoplasm
25%
Hope
25%
Adjuvant Therapy
25%
Postoperative Recovery
25%
Nursing and Health Professions
Pancreas Cancer
100%
Neoadjuvant Therapy
100%
Postoperative Care
50%
Chemoradiotherapy
50%
Diseases
50%
Neoplasm
25%
Cancer Mortality
25%
Adjuvant Therapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Chemoradiation Therapy
66%
Diseases
66%
Cancer Mortality
33%
Neoplasm
33%